• 1. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 2. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 3. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 4. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 5. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines Imidazopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines

Recent Advances in the Study of 6-fluoro-Imidazo[1,2-a]pyridine-2-methanol (CAS: 1038827-63-2): A Promising Scaffold in Medicinal Chemistry

The compound 6-fluoro-Imidazo[1,2-a]pyridine-2-methanol (CAS: 1038827-63-2) has recently emerged as a significant scaffold in medicinal chemistry due to its versatile pharmacological properties. This heterocyclic structure, characterized by the presence of a fluorine atom at the 6-position and a hydroxymethyl group at the 2-position, has been the focus of numerous studies aimed at exploring its potential in drug discovery and development. The unique structural features of this molecule contribute to its ability to interact with various biological targets, making it a promising candidate for the treatment of multiple diseases.

Recent research has highlighted the role of 6-fluoro-Imidazo[1,2-a]pyridine-2-methanol in the development of novel therapeutic agents, particularly in the areas of oncology, infectious diseases, and central nervous system (CNS) disorders. The compound's ability to modulate key signaling pathways and its favorable pharmacokinetic properties have been demonstrated in preclinical studies. For instance, a 2023 study published in the Journal of Medicinal Chemistry reported that derivatives of this scaffold exhibited potent inhibitory activity against specific kinase targets implicated in cancer progression, with IC50 values in the nanomolar range.

In addition to its anticancer potential, 6-fluoro-Imidazo[1,2-a]pyridine-2-methanol has shown promise as an antimicrobial agent. A recent study in Bioorganic & Medicinal Chemistry Letters (2024) revealed that certain analogs of this compound displayed significant activity against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The researchers attributed this activity to the molecule's ability to disrupt bacterial cell wall synthesis and inhibit essential enzymes involved in microbial metabolism.

The synthetic routes to 6-fluoro-Imidazo[1,2-a]pyridine-2-methanol have also been optimized in recent years, with several research groups reporting improved yields and selectivity. A 2023 paper in Organic Process Research & Development described a scalable, cost-effective synthesis of this scaffold using a one-pot multicomponent reaction strategy. This advancement is particularly significant for the pharmaceutical industry, as it facilitates the large-scale production of derivatives for further biological evaluation.

Structural-activity relationship (SAR) studies have provided valuable insights into the pharmacophoric features of 6-fluoro-Imidazo[1,2-a]pyridine-2-methanol that contribute to its biological activity. Computational modeling and X-ray crystallography studies have revealed that the fluorine atom at the 6-position enhances the molecule's binding affinity to target proteins through favorable electrostatic interactions, while the hydroxymethyl group at the 2-position serves as a versatile handle for further chemical modifications to optimize drug-like properties.

Looking forward, the 6-fluoro-Imidazo[1,2-a]pyridine-2-methanol scaffold presents exciting opportunities for the development of next-generation therapeutics. Current research efforts are focused on exploring its potential in targeted drug delivery systems and combination therapies. With its demonstrated versatility and the growing body of supporting evidence, this compound is poised to make significant contributions to the field of medicinal chemistry in the coming years.

• 367900-94-5(6-Fluoroimidazo[1,2-a]pyridine-2-carboxylic acid)
• 1197002-76-8(6-fluoro-imidazo[1,2-a]pyridine-2-carboxylic acid hcl)
• 872363-02-5((5-Methylimidazo1,2-apyridin-2-yl)methanol)
• 178488-39-6((5-Methylimidazo1,2-apyridin-3-yl)methanol)
• 30489-43-1({imidazo[1,2-a]pyridin-3-yl}methanol)
• 1020034-56-3(8-Fluoroimidazo[1,2-a]pyridine-2-carboxylic acid)
• 367500-94-5(6-Fluoroimidazo[1,2-a]pyridine-2-carboxylic acid)
• 1019021-85-2(6-Fluoroimidazo[1,2-a]pyridine-3-carboxylic acid)
• 82090-52-6({imidazo[1,2-a]pyridin-2-yl}methanol)
• 881841-32-3(6-Fluoroimidazo[1,2-a]pyridine-2-carbaldehyde)